Mobile

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECT...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-009214-40

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECTED SUBJECTS

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Determine if the addition of filibuvir to a standard of care (SOC) regimen of pegylated interferon alpha 2a (Pegasys) and ribavirin (Copegus) significantly increases the proportion of subjects who achieve a sustained viral response (SVR) - undetectable HCV RNA at week 72 compared to pegIFN/RBV alone.

Critère d'inclusion

  • Treatment of chronic HCV genotype 1 infection

Liens